All
Novel Nanoparticle Formulation Fights SCC
July 1st 2003Chicago - A novel nanoparticle formulation of paclitaxel (ABI-007) administered intra-arterially has been shown to be well tolerated and very active against squamous carcinomas of the head and neck, uterus, and anal canal, Bruno Damascelli, M.D., said at the 39th annual meeting of the American Society of Clinical Oncology.
In Search of Complete Remission
July 1st 2003San Francisco - Confirming a diagnosis and individualizing treatment are primary goals in the treatment of patients with cutaneous T cell lymphoma (CTCL), as is striving for complete remission, Eric C. Vonderheid, M.D., said at the annual meeting of the American Academy of Dermatology.
Overview of Efalizumab Patient-reported Outcomes Trials
July 1st 2003After treatment with the new biologic agents, patient-reported outcomes measuring quality of life were evaluated, since psoriasis has been shown to have a significantly negative impact on patients' physical, psychological, and social functioning.22 Because the condition can affect the ability to perform normal work activities and often causes absence from work, psoriasis can negatively affect a person's job and income.